Navigation Links
Paul Capital Partners Promotes Ken Macleod To Partner
Date:7/23/2008

--Reflects Fund's Commitment to Meet the Financing Needs of European and

Asian Healthcare Companies and Institutions--

NEW YORK, July 24 /PRNewswire/ -- Paul Capital Partners today announced that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul Capital's London office, Dr. Macleod is responsible for sourcing, evaluating and negotiating European and Asian healthcare investment opportunities for the Paul Capital Healthcare funds.

"Since he joined Paul Capital four years ago, Ken has strengthened our presence in the European and Asian healthcare markets and helped us form many mutually beneficial partnerships," said Walter Flamenbaum, M.D., a Partner of Paul Capital Partners. "He embodies our commitment to helping healthcare companies, institutions and inventors advance their goals by identifying strategic solutions to their financial and asset management needs. Ken's promotion to Partner reflects his demonstrated ability to identify promising healthcare investment opportunities and underscores Paul Capital's dedication to expanding its position in the global healthcare arena."

Most recently, in April 2008, Paul Capital Healthcare invested up to $28 million in Plethora Solutions Holdings PLC and euro 18.4 million in Vernalis plc, both of which are based in the U.K. To date, the Paul Capital Healthcare funds have invested $395 million in 14 transactions in Europe and Asia.

"A growing number of European and Asian healthcare companies and institutions recognize that in order to realize their innovative potential they require an equally innovative approach to creating value and accessing capital," said Dr. Macleod. "With more than $940 million committed to 37 healthcare investments, and similar leadership in the areas of private equity secondaries and venture capital funds of funds, Paul Capital provides funds that help leading-edge companies, institutions and individuals meet diverse strategic objectives. I am very pleased to become a partner of this highly regarded team."

Dr. Macleod provides a strong operational background in the pharmaceutical and biotechnology industries, where he previously held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.

About Paul Capital Partners and Paul Capital Healthcare

Founded in 1991, Paul Capital manages $6.6 billion in capital commitments for its three investment platforms that include private equity secondaries, healthcare royalty and revenue interests, and venture capital fund of funds. The firm has offices in Hong Kong, London, New York, Paris, San Francisco, Sao Paulo and Toronto.

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com.

Contact:

Paul Capital Partners

Ken Macleod, Partner

Tel: +44(0)20-7514-0754

Email: kmacleod@paulcap.com

Joshua Glaser, Director of Investor Relations

Tel: +1-646-264-1169

Email: jglaser@paulcap.com

Lazar Partners

Stephanie Seiler

Tel: +1-646-871-8487

Tel: +1-206-713-0124

Email: sseiler@lazarpartners.com


'/>"/>
SOURCE Paul Capital Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology: